Targeted Re-Sequencing Emulsion PCR Panel for Myopathies: Results in 94 Cases

• Published in: Journal of neuromuscular diseases Vol. 3; no. 2; p. 209
• Main Authors: Punetha, Jaya, Kesari, Akanchha, Uapinyoying, Prech, Giri, Mamta, Clarke, Nigel F, Waddell, Leigh B, North, Kathryn N, Ghaoui, Roula, O'Grady, Gina L, Oates, Emily C, Sandaradura, Sarah A, Bönnemann, Carsten G, Donkervoort, Sandra, Plotz, Paul H, Smith, Edward C, Tesi-Rocha, Carolina, Bertorini, Tulio E, Tarnopolsky, Mark A, Reitter, Bernd, Hausmanowa-Petrusewicz, Irena, Hoffman, Eric P
• Format: Journal Article
• Language: English
• Published: Netherlands 27-05-2016
• Subjects: Genetic Testing; High-Throughput Nucleotide Sequencing; Humans; Molecular Diagnostic Techniques; Muscular Diseases - diagnosis; Muscular Diseases - genetics; Muscular Dystrophies - diagnosis; Muscular Dystrophies - genetics; Mutation; Polymerase Chain Reaction; Sequence Analysis, DNA; Exome; molecular diagnostics; genetic screening; massively-parallel sequencing; high-throughput DNA sequencing; myopathies; Muscular dystrophy; molecular diagnostic testing
• ISSN: 2214-3599
• DOI: 10.3233/JND-160151

Molecular diagnostics in the genetic myopathies often requires testing of the largest and most complex transcript units in the human genome (DMD, TTN, NEB). Iteratively targeting single genes for sequencing has traditionally entailed high costs and long turnaround times. Exome sequencing has begun to supplant single targeted genes, but there are concerns regarding coverage and needed depth of the very large and complex genes that frequently cause myopathies.
To evaluate efficiency of next-generation sequencing technologies to provide molecular diagnostics for patients with previously undiagnosed myopathies.
We tested a targeted re-sequencing approach, using a 45 gene emulsion PCR myopathy panel, with subsequent sequencing on the Illumina platform in 94 undiagnosed patients. We compared the targeted re-sequencing approach to exome sequencing for 10 of these patients studied.
We detected likely pathogenic mutations in 33 out of 94 patients with a molecular diagnostic rate of approximately 35%. The remaining patients showed variants of unknown significance (35/94 patients) or no mutations detected in the 45 genes tested (26/94 patients). Mutation detection rates for targeted re-sequencing vs. whole exome were similar in both methods; however exome sequencing showed better distribution of reads and fewer exon dropouts.
Given that costs of highly parallel re-sequencing and whole exome sequencing are similar, and that exome sequencing now takes considerably less laboratory processing time than targeted re-sequencing, we recommend exome sequencing as the standard approach for molecular diagnostics of myopathies.